Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Niagen Bioscience (NAGE) over the last 12 years, with Q3 2025 value amounting to $292000.0.

  • Niagen Bioscience's Current Deferred Revenue rose 5869.57% to $292000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $292000.0, marking a year-over-year increase of 5869.57%. This contributed to the annual value of $611000.0 for FY2024, which is 21333.33% up from last year.
  • Latest data reveals that Niagen Bioscience reported Current Deferred Revenue of $292000.0 as of Q3 2025, which was up 5869.57% from $303000.0 recorded in Q2 2025.
  • In the past 5 years, Niagen Bioscience's Current Deferred Revenue registered a high of $611000.0 during Q4 2024, and its lowest value of $141000.0 during Q1 2022.
  • Its 5-year average for Current Deferred Revenue is $214055.6, with a median of $179500.0 in 2021.
  • As far as peak fluctuations go, Niagen Bioscience's Current Deferred Revenue plummeted by 4208.63% in 2021, and later soared by 21333.33% in 2024.
  • Niagen Bioscience's Current Deferred Revenue (Quarter) stood at $161000.0 in 2021, then fell by 2.48% to $157000.0 in 2022, then rose by 24.2% to $195000.0 in 2023, then surged by 213.33% to $611000.0 in 2024, then crashed by 52.21% to $292000.0 in 2025.
  • Its Current Deferred Revenue was $292000.0 in Q3 2025, compared to $303000.0 in Q2 2025 and $207000.0 in Q1 2025.